Executive Summary
Integrated BioPharma Inc (INBP) reported QQ1 2025 revenue of $13.617 million, a year-over-year decline of 45.5% from $24.998 million in QQ1 2024, reflecting a difficult base effect in a small-mcale nutraceuticals-focused franchise. Despite the revenue contraction, the company posted a resilient gross profit of $1.371 million and an EBITDA of $0.81 million, with operating income of $0.49 million and a net income of $0.259 million for the quarter. The quarterly results translate to a gross margin of ~10.07% and an operating margin of ~3.60%, with a net margin of ~1.90%. Cash flow was positive, with cash provided by operations of $0.657 million and free cash flow of $0.601 million, ending the period with roughly $2.271 million in cash and a net cash position of about $0.713 million after accounting for debt.
Key Performance Indicators
QoQ: 21.89% | YoY:1 007.41%
QoQ: -3.36% | YoY:538.98%
QoQ: -3.37% | YoY:530.00%
Key Insights
Revenue: $13.617 million in Q1 2025; YoY -45.53%; QoQ +6.83%
Gross Profit: $1.371 million; YoY +64.78%; QoQ +6.78%; Gross Margin: 10.07%
Operating Income: $0.490 million; YoY +1,007.41%; QoQ +21.89%; Operating Margin: 3.60%
EBITDA: $0.810 million; EBITDARatio: 5.95%
Net Income: $0.259 million; YoY +538.98%; QoQ -3.36%; Net Margin: 1.90%
EPS (basic): $0.0086; EPS (diluted): $0.0085; YoY EPS growth: +530%; QoQ: -3.37%
Cash Flow: Net cash from operating activities $0.657 million; Capex $-0.056 mill...
Financial Highlights
Revenue: $13.617 million in Q1 2025; YoY -45.53%; QoQ +6.83%
Gross Profit: $1.371 million; YoY +64.78%; QoQ +6.78%; Gross Margin: 10.07%
Operating Income: $0.490 million; YoY +1,007.41%; QoQ +21.89%; Operating Margin: 3.60%
EBITDA: $0.810 million; EBITDARatio: 5.95%
Net Income: $0.259 million; YoY +538.98%; QoQ -3.36%; Net Margin: 1.90%
EPS (basic): $0.0086; EPS (diluted): $0.0085; YoY EPS growth: +530%; QoQ: -3.37%
Cash Flow: Net cash from operating activities $0.657 million; Capex $-0.056 million; Free cash flow $0.601 million
Liquidity/Balance Sheet: Cash $2.271 million; Total assets $26.183 million; Total liabilities $6.633 million; Total debt $1.558 million; Net debt = -$0.713 million; Retained earnings = -$31.968 million; Total stockholders’ equity $19.550 million; Current ratio 3.04; Quick ratio 1.176; Inventory $11.224 million; Net receivables $4.385 million; Inventory turns ~1.09; Receivables turnover ~3.11
Valuation/Efficiency: Price/Earnings ratio data not provided for INBP; Price-to-book ~0.361x; ROA ~0.99%; ROE ~1.32%; Asset turnover ~0.52x; Operating cash flow per share ~0.0218; Free cash flow per share ~0.0200.
Note: All data reflect the QQ1 2025 quarter (period ended 2024-09-30 in the filing cycle data) and surrounding 4-quarter history included in the provided dataset.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
13.62M |
-45.53% |
6.83% |
| Gross Profit |
1.37M |
64.78% |
6.78% |
| Operating Income |
490.00K |
1 007.41% |
21.89% |
| Net Income |
259.00K |
538.98% |
-3.36% |
| EPS |
0.01 |
530.00% |
-3.37% |
Key Financial Ratios
operatingProfitMargin
3.6%
operatingCashFlowPerShare
$0.02
freeCashFlowPerShare
$0.02
Management Commentary
No earnings call transcript was provided in the dataset. Consequently, there are no management quotes or theme-based highlights to extract. The analysis relies entirely on the Q1 2025 10-Q data as the basis for assessment and forward-leaning commentary.
Forward Guidance
No formal forward guidance was disclosed in INBP's QQ1 2025 filing. Given the absence of explicit targets, the forward view hinges on qualitative signals from the company’s mix of activities (Contract Manufacturing and Other Nutraceuticals) and the potential for margin improvement through fixed-cost leverage and product mix. Our qualitative assessment suggests a cautious path to profitability if revenue stabilizes and cost controls persist. Key factors investors should monitor: (1) quarterly revenue trends and segment mix (Contract Manufacturing vs. Other Nutraceuticals); (2) progression of gross margin expansion and cost discipline; (3) working capital dynamics and cash conversion; (4) any announced share actions, financing changes, or debt reduction; (5) development of private-label and e-commerce channels that could scale revenue without proportionate SG&A.
Conclusion: In the near term, INBP’s trajectory will depend on topline stabilization and continued, disciplined cost management, with evolving visibility from management on upcoming initiatives.